Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | USP2 | O75604 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14960278 | 0.95 | MEN1 (0.42) | PDE10ANOS2TLR7KMT2AMEN1 | |
| SCHEMBL1550581 | 0.94 | MEN1 (0.44) | PDE10ANOS2TLR7KMT2AMEN1 | |
| SCHEMBL27832688 | 0.94 | TLR9 (0.45) | PDE10ANOS2TLR7KMT2AMEN1 | |
| SCHEMBL28580708 | 0.90 | PDE10A (0.46) | PDE10ANOS2TLR7KMT2AMEN1 | |
| SCHEMBL28603226 | 0.84 | TLR9 (0.47) | PDE10ANOS2TLR7KMT2AMEN1 | |
| SCHEMBL18083005 | 0.83 | TLR7 (0.46) | PDE10ANOS2TLR7KMT2ARAB9A | |
| SCHEMBL7068584 | 0.78 | PDE10A (0.71) | PDE10AKMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL28594904 | 0.78 | PDE10A (0.50) | PDE10ATLR7RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL9936785 | 0.78 | KDM4E (0.51) | NOS2TLR7KMT2AMEN1POLB | |
| SCHEMBL18082996 | 0.77 | KCNH2 (0.45) | PDE10ANOS2TLR7KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2691377-B1 | AMINOQUINOXALINE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENT (C N R S ) (FR) | 2018-03-07 | — | — | EP | disclosed |
| US-9434701-B2 | Aminoquinoxaline derivatives for treatment of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-06 | — | — | US | disclosed |
| US-9434701-B2 | Aminoquinoxaline derivatives for treatment of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-06 | — | — | US | disclosed |
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| WO-2012131080-A1 | AMINOQUINOXALINE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-10-04 | — | — | WO | disclosed |
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
| EP-2313373-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Centre National de la Recherche Scientifique (C.N.R.S) (FR) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010007179-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007179-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HCRTR2, HCRTR1, CHRNA2 | PDE10A 2019/4885NOS2 1281/4885TLR7 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.